GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 1 of 49 
 
CLINICAL TRIAL PROTOCOL 
 
 
 
  Trial Title  Efficacy and safety of GMRx2 ( a single pill combination containing 
telmisartan/amlodipine/indapamide) compared to dual combinations for the 
treatment of hypertension: An international, multi-center, randomized, double-
blind, active-controlled, parallel-group trial 
 Brief Title  Efficacy and safety of GMRx2 compared to dual combinations for the treatment of 
hypertension 
 
Phase of Development  Phase III  
 
Trial Drug  GMRx2: Single pill  combination of telmisartan/amlodipine/indapamide  
Dose version 2: telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg  
Dose version 3: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg 
 Trial Number  GMRx2 -HTN -2020 -ACT1  
 
Indication  Hypertension  
 
Protocol Version  Version  6.0, 10 Oc tober 2023  
 
Trial  Registration  Clinicaltrials.gov [STUDY_ID_REMOVED]  
 
Sponsor  George Medicines Pty Limited  
 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 2 of 49 
STATEMENT OF COMPLIANCE 
 
The trial will be conducted in accordance with the International Conference on Harmonization Good Clinical 
Practice (ICH-GCP), applicable ethical and regulatory requirements. The Site Investigators will assure that no 
deviation from, or changes to the protocol will take place without prior agreement from the sponsor and 
documented approval from the Institutional Review Board (IRB) or Ethics Committee (EC), except where 
necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct 
of this trial will have completed ICH-GCP Training. 
 
The protocol, participant information sheet and consent form(s) (PISCF), recruitment materials, and all 
participant materials will be submitted to the IRB/EC for review and approval.  Approval of both the protocol 
and the PISCF must be obtained before any participant is enrolled.  Any amendment to the protocol will require 
review and approval by the IRB/EC before the changes are implemented to the study.  All changes to the PISCF 
will be IRB/EC approved; a determination will be made regarding whether a new consent needs to be obtained 
from participants who provided consent, using a previously approved consent form. 
 
Alterations to the trial conduct in the context of the coronavirus pandemic 
In the context of the COVID-19 pandemic, alterations may be required to trial conduct during the course of 
the trial. These include home delivery of trial medications, conduct of virtual visits and virtual monitoring as 
detailed in the trial’s COVID-19 Risk Management & Mitigation plan. Any such alterations should be 
implemented in keeping with the FDA Guidance on Conduct of Clinical Trials of Medical Products during 
COVID-19 Public Health Emergency Guidance for Industry, Investigators, and Institutional Review Boards, 
March 2020, Updated on May 14, 2020 and any subsequent revisions and any relevant guidance from other 
regulatory bodies. Any such changes should be documented, according to the procedures in this guidance. 
   
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 3 of 49 
Contents 
 CONTACT LIST ......................................................................................................................................... 7 
1.1. Trial Sponsor 7 
1.2. Academic Coordinating Center 7 
 VERSION HISTORY ................................................................................................................................... 8 
 ROLES & RESPONSIBILITIES ..................................................................................................................... 8 
3.1. Steering Committee 8 
3.2. Data and Safety Monitoring Board 9 
3.3. Trial Sponsor 9 
3.4. Contract Research Organizations 9 
3.5. Academic Coordinating Center 9 
3.6. Endpoint Adjudication Committee 9 
3.7. Names, Affiliations & Roles of Protocol Contributors 9 
 PROTOCOL SYNOPSIS............................................................................................................................ 10 
 INTRODUCTION .................................................................................................................................... 12 
5.1. Burden of High Blood Pressure and Current Treatment Gaps 12 
5.2. Potential Role of Single Pill Combinations, Including for Initial Treatment 12 
5.3. Potential Role of Triple Low-Dose Combination Therapy 13 
5.4. The TRIUMPH Trial of Triple Low-Dose Combination Therapy 13 
5.5. The QUARTET trial of quadruple quarter-dose combination 14 
5.6. Need for a New Triple Low-Dose Combination 15 
5.7. Expected Effects of GMRx2 15 
 OBJECTIVES ........................................................................................................................................... 16 
6.1. Primary Objective 16 
6.2. Secondary Objectives 17 
 TRIAL DESIGN ........................................................................................................................................ 17 
7.1. Trial Design Rationale 17 
7.2. Sub-studies 17 
 METHODS: PARTICIPANTS, INTERVENTION & OUTCOMES .................................................................. 18 
8.1. Trial Setting & Participant Recruitment 18 
8.2. Participant Eligibility 18 
 Inclusion Criteria ....................................................................................................................... 18 
 Exclusion Criteria ....................................................................................................................... 18 
8.3. Trial Schema 21 
8.4. Intervention 21 
 Single-Blind Active Run-In Period .............................................................................................. 21 
 Double-Blind Treatment Period ................................................................................................ 21 
8.5. Adherence to Trial Medication 22 
8.6. Add-on Treatment for Participants with High BP 22 
8.7. Down-Titration or Temporary Cessation of Randomized Trial Medication 22 
8.8. Early Permanent Discontinuation of Trial Medication 23 
8.9. Post-Trial Medication 23 
 OUTCOMES ........................................................................................................................................... 23 
9.1. Efficacy Outcomes 23 
 Primary ...................................................................................................................................... 23 
 Secondary .................................................................................................................................. 23 
9.2. Safety Outcomes 24 
 Primary ...................................................................................................................................... 24 
 Secondary .................................................................................................................................. 24 
 Descriptive Safety Outcomes .................................................................................................... 24 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 4 of 49 
9.3.  25 
 PARTICIPANT TIMELINE & ASSESSMENTS ............................................................................................ 26 
10.1. Schedule of Evaluations 26 
10.2. Visit Procedures 27 
 Written Informed Consent ........................................................................................................ 27 
 Verbal Consent .......................................................................................................................... 27 
 Assessment of Participant Eligibility ......................................................................................... 28 
 Medical History ......................................................................................................................... 28 
 Physical Examination ................................................................................................................. 28 
 Anthropometric Measurements ............................................................................................... 28 
 Clinic BP Measurement ............................................................................................................. 28 
 Home BP Measurement ............................................................................................................ 28 
 Electrocardiogram ..................................................................................................................... 28 
 Laboratory Investigations ......................................................................................................... 29 
 Allocation of Trial Medication ................................................................................................... 29 
 Dispensation of Trial Medication .............................................................................................. 29 
 Returning of Trial Medication ................................................................................................... 29 
 Concomitant Treatments .......................................................................................................... 29 
10.3. Visit Details 29 
 Pre-Screening Visit (As Required) ............................................................................................. 29 
 Screening Visit ........................................................................................................................... 30 
 Re-Screening ............................................................................................................................. 30 
 Extended Run-In ........................................................................................................................ 30 
 Pre-Randomization visit ............................................................................................................ 31 
 Randomization Visit .................................................................................................................. 31 
 Week 6 Visit .............................................................................................................................. 31 
 Week 12 Visit ............................................................................................................................ 31 
 Week 16 visit (End of Trial Visit) ............................................................................................... 32 
 METHODS: ASSIGNMENT OF INTERVENTION ....................................................................................... 32 
11.1. Allocation Sequence Generation 32 
11.2. Allocation Concealment 32 
11.3. Blinding (Masking) 32 
11.4. Unblinding 32 
 Unblinding of Trial Medication for Expedited Safety Reporting ............................................... 32 
 Unblinding of Trial Medication in a Clinical Emergency ........................................................... 32 
 METHODS: DATA COLLECTION, MANAGEMENT & STATISTICAL ANALYSIS ......................................... 32 
12.1. Data Collection 32 
12.2. Data Management 33 
12.3. Sample Size & Power Calculation 33 
12.4. Statistical Methods 33 
  WITHDRAWAL FROM TRIAL PARTICIPATION ........................................................................................ 34 
 TRIAL MEDICATION MANAGEMENT ..................................................................................................... 34 
14.1. Manufacturing 34 
14.2. Packaging, Labelling, Distribution & Storage 34 
14.3. Return & Destruction 34 
 MANAGING INTERRUPTION OF STUDY MATERIAL SUPPLY TO TRIAL CENTRES ................................... 34 
 MONITORING........................................................................................................................................ 35 
16.1. Data & Safety Monitoring Board 35 
16.2. Data Monitoring 35 
 SAFETY .................................................................................................................................................. 35 
17.1. Safety Definitions 35 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 5 of 49 
 Adverse Event ........................................................................................................................... 35 
 Adverse Event of Special Interest ............................................................................................. 35 
 Serious Adverse Event ............................................................................................................... 35 
 Intensity/Severity of an AESI/SAE ............................................................................................. 35 
 Relationship to the Trial Medication ........................................................................................ 36 
 Serious Unexpected Suspected Adverse Reaction.................................................................... 36 
17.2. Safety Reporting 36 
 AESI/SAE Data Collection & Follow-Up Period .......................................................................... 36 
 Trial Investigator Responsibilities in Reporting AESIs/SAEs ...................................................... 36 
 Reporting of AESIs & SAEs ......................................................................................................... 36 
 Reporting of SUSARs ................................................................................................................. 37 
 Reporting of Pregnancy ............................................................................................................. 37 
 Reporting of Trial Medication Use Errors or Misuse................................................................. 37 
 ETHICAL & REGULATORY COMPLIANCE ............................................................................................... 37 
18.1. Ethical Approval 37 
18.2. Regulatory Approval 37 
18.3. Confidentiality 37 
18.4. Protocol Amendments 37 
18.5. Adherence to the Trial Protocol 38 
  ADMINISTRATIVE SECTION ................................................................................................................... 38 
19.1. Insurance 38 
19.2. Quality Assurance 38 
19.3. Trial Documents Retention 38 
19.4. Ownership, Disclosure of Data and Dissemination policy 38 
 APPENDICES .......................................................................................................................................... 39 
20.1. Appendix 1: List of Abbreviations 39 
20.2. Appendix 2: Procedure for the Measurement of Clinic BP 41 
20.3. Appendix 3: Procedure for the Measurement of Home BP 42 
20.4. Appendix 4: Trial Organization 43 
20.5. Appendix 5: Prohibited Drugs During the Trial 44 
20.6. Appendix 6: Protocol Signature Page 45 
 REFERENCES.......................................................................................................................................... 46 
 
 
  
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 6 of 49 
FIGURES 
Figure 1: Blood pressure over time in the TRIUMPH trial of triple low-dose combination as initial/early treatment vs 
usual care for hypertension ................................................................................................................................ 14  
Figure 2: Trial design summary ......................................................................................................................................... 17  
Figure 3: Trial schema ....................................................................................................................................................... 21 
 
 
TABLES 
 
Table 1: Short-term RCTs of triple or quadruple low-dose combination therapy ............................................................ 13  
Table 2: Adverse events with the lowest approved dose of GMRx2 components vs placebo in previous randomized 
trials .................................................................................................................................................................... 16  
Table 3: Percentage with symptoms attributable to treatment (treated minus placebo) in previous randomized trials 
of lowest-dose monotherapy of GMRx2 component drug classes ..................................................................... 16  
Table 4: Treatment Groups in the Trial ............................................................................................................................. 22 
Table 5: Trial visits schedule and assessments Randomization Period............................................................................. 26  
 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 7 of 49 
 CONTACT LIST 
1.1. Trial Sponsor 
 
George Medicines  
 
1.2. Academic Coordinating Center 
The George Institute for Global Health 
Level 5, 1 King Street 
Newtown, Sydney, NSW 2042, Australia 
 
 
 
  

GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 12 of 49 
 INTRODUCTION 
5.1. Burden of High Blood Pressure and Current Treatment Gaps  
High blood pressure (BP) is a leading cause of preventable morbidity and mortality globally.1 The benefits of 
BP lowering in reducing cardiovascular (CV) events are well established2 and there is clear evidence that 
greater BP lowering confers a greater reduction in CV events.3-5 However, globally, control of high BP is poor, 
with only one in three treated patients achieving traditional BP goals.6,7 Most treated patients receive only 
monotherapy, despite guidelines recognizing that the large majority of patients require multiple drugs to 
achieve goal BP.6  There is broad consensus among leading international authorities that key factors driving 
this treatment gap are under treatment of hypertension with monotherapy in most patients.8 In the United 
States of America (USA), about 40% of treated patients receive monotherapy and this has not changed 
between 2005 and 2016.9 Given the recommendations in recent guidelines for target BPs below 130/80 mmHg 
for high-risk patients, the need for effective, tolerable, and affordable therapy is even more imperative.   
5.2. Potential Role of Single Pill Combinations, Including for Initial Treatment 
Historically, hypertension management guidelines have recommended initiating pharmacological treatment 
with monotherapy, with treatment modification (dose up-titration, or adding other drugs) at multiple follow-
up visits. However, in practice, most patients remain uncontrolled on monotherapy for numerous reasons, 
both patient- and physician-related. Lack of adherence to prescribed BP-lowering drugs is a major risk factor 
for poor BP control10 and is worsened by the increased number of pills,11 higher co-payment, adverse drug 
effects, and a poor patient-provider relationship.12-14 ‘Therapeutic inertia’ - the reluctance of physicians to 
initiate or intensify or modify treatment appropriately has also been identified as an important barrier to 
hypertension control.15,16  
 
Combination therapy has the potential to address many of the aforementioned barriers. A recent systematic 
review of 13 trials with 13,095 participants demonstrated initial low-dose dual combination therapy improved 
BP control compared to monotherapy, without an increase in adverse effects.17 Dual combination therapy 
achieves about five times more BP-lowering than doubling the dose of monotherapy18 and adding a third drug 
is several times more effective than increasing the dose of dual combination.17 Two pragmatic randomized 
controlled trials (RCTs) have assessed strategies, rather than mandatory regimens,  comparing initial dual 
combination therapy with monotherapy, with each showing benefits with the former. The STITCH trial 
compared initial therapies of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker 
(ARB) + thiazide diuretic combination with monotherapy and showed improved BP control with combination 
therapy in a primary care setting.19 The STRAtegies of Treatment in Hypertension: Evaluation (STRATHE) trial 
compared initial combination therapy with stepped care and up-titration and showed improved BP control 
without adverse effects with the initial combination therapy.20 Furthermore, in the Prevention And Treatment 
of Hypertension With Algorithm-based Therapy - study 1 (PATHWAY-1) trial,21 combination of losartan and 
hydrochlorothiazide (HCTZ) as initial treatment was superior to monotherapy with either drug alone, with no 
difference in withdrawals due to adverse events (AEs). This trial also demonstrated that the initial combination 
was uniformly more effective than monotherapy, whether monotherapy was personalized by prediction of 
each patient’s best drug (e.g. using renin levels or age) or by systematic crossover between monotherapy 
options. Recent hypertension guidelines, including the 2018 European Society of Cardiology/European Society 
of Hypertension (ESC/ESH) Guideline,22 the 2020 International Society of Hypertension Guideline23  and the 
2021 WHO Hypertension Guideline24 recommend combination therapy as initial treatment for many or most 
patients and the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline,25 
recommends combination therapy as an initial treatment among patients with BP >140/90 mmHg and average 
BP more than 20/10 mm Hg above their BP target. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 14 of 49 
5.5. The QUARTET trial of quadruple quarter-dose combination 
QUARTET was a multicenter, double-blind, parallel-group, randomized, trial among Australian adults with 
hypertension, who were untreated or receiving single BP-lowering drug.33 Participants were randomly 
assigned to initial quadruple quarter dose (containing irbesartan 37·5 mg, amlodipine 1·25 mg, indapamide 
0·625 mg, and bisoprolol 2·5 mg) or monotherapy control (irbesartan 150 mg). Additional medications could 
be added in both groups among those not at control during follow-up, starting with amlodipine 5 mg. A total 
Figure 2: Blood pressure over time in the QUARTET trial of quadruple quarter-dose combination as initial/early 
treatment vs initial monotherapy for hypertension  
 
Figure 1: Blood pressure over time in the TRIUMPH trial of triple low -dose combination as initial/early 
treatment vs usual care for hypertension  
 

GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 15 of 49 
of 591 participants were randomized with baseline mean unattended office BP 141/85 mmHg (standard office 
153/89 mmHg). By 12 weeks, 44 (15%) of 300 participants had additional BP medications in the intervention 
group compared with 115 (40%) of 291 participants in the control group. As seen in Figure , SBP was lower by 
6·9 mm Hg (95% CI 4·9–8·9; p<0·0001) and BP control was higher in the intervention group compared with 
control group (76% vs 58%; relative risk [RR] 1·30, 95% CI 1·15–1·47; p<0·0001). There was no difference in 
adverse event related treatment withdrawals at 12 weeks (intervention 4·0% vs control 2·4%; p=0·27). Among 
the 417 patients who continued in the randomized groups to 12 months, up-titration occurred more 
frequently among control participants than intervention participants (p<0·0001). However, at 12 months 
mean unattended SBP remained lower by 7·7 mm Hg (95% CI 5·2–10·3) and BP control was higher in the 
intervention group compared with control group (81% vs 62%; RR 1·32, 95% CI 1·16–1·50).  
5.6. Need for a New Triple Low-Dose Combination 
Currently available triple single pill combinations (SPCs) of BP-lowering drugs are only indicated for 
substitution among patients already taking all the three-component drugs or as an add-on/switch therapy 
among patients not adequately controlled on two of the component drugs. 34-36 None of the available triple 
SPCs are indicated for initial treatment. Furthermore, there are no existing SPC products with low-doses of an 
ARB, calcium channel blocker (CCB) and a thiazide-like diuretic. To address this unmet need, GM developed a 
new SPC containing telmisartan, amlodipine and indapamide (GMRx2) in three strengths (10/1.25/0.625 mg, 
20/2.5/1.25 mg, and 40/5/2.5 mg, dose versions 1, 2 and 3 respectively).  
 
Hypertension guidelines recommend ACEI, ARB, CCB, and thiazide-like diuretics as first-line therapies for the 
treatment of hypertension, with some also recommending HCTZ. ARBs are more tolerable than ACEIs given 
that they do not cause cough and are also about three-times less likely to cause angioedema than ACEIs among 
black patients.37 The most reliable comparisons of ARBs with ACEIs are direct randomized comparisons, and 
these do not show a difference in efficacy in reducing CV events between the two classes but demonstrate 
reduced AEs with ARBs.38-40  Telmisartan has the longest half-life (~24 hours) of the ARBs 41 and provides 
superior or similar BP reduction compared to the commonly used ACEIs.42 Among CCBs, amlodipine has been 
used most commonly in CV outcome trials, has fewest interactions with other products (compared, for 
example, to diltiazem) and has a long half-life (30–50 hours). Thiazide-like diuretics such as indapamide and 
chlorthalidone are superior to thiazide diuretics in reducing BP without increasing metabolic AEs.27,43,44 The 
most consistent and robust evidence of CV events reduction comes from trials involving indapamide or 
chlorthalidone.45,46 Compared to HCTZ, indirect comparisons of the results from RCTs indicate a modest 
additional reduction in CV events and heart failure with thiazide-like diuretics (indapamide and chlorthalidone) 
compared to thiazide diuretics, after correcting for differences in clinic BP reductions.47,48 Indapamide has a 
half-life of 16 to 18 hours,49 and is widely available internationally.   
5.7. Expected Effects of GMRx2 
The placebo-corrected systolic BP (SBP)-lowering efficacy of GMRx2 dose versions 1, 2 and 3 from a baseline 
SBP of 150 mmHg are estimated to be approximately 13 mmHg, 18 mmHg and 25 mmHg, respectively.4 This 
would represent a clinically important BP reduction in comparison to standard-dose monotherapy which 
reduces SBP by 8-9 mmHg, with each doubling of dose conferring only a 1-2 mmHg incremental SBP 
reduction.18,27 Dual combinations typically also have a difference of only 1-2 mmHg between neighboring dose 
versions and a maximum SBP reduction of around 20 mmHg with maximal dose of both drugs.4,18,27 The 
reasoning in developing GMRx2 is, therefore, in line with USA Food & Drug Administration (FDA) observations 
which have stated: “Over the last decade, the Agency has actively discouraged antihypertensive monotherapy 
and combination doses with effects that were very close together, considering them a nuisance to physicians 
seeking to get patients to goal.” 50 
 
RCTs of the lowest-approved dose of monotherapy telmisartan 20 mg, amlodipine 2.5 mg and indapamide 
1.25 mg have demonstrated no statistically significant increase in adverse effects compared to placebo (Table 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 17 of 49 
6.2. Secondary Objectives 
To assess the safety of GMRx2 compared to each of the three dual combinations of component drugs of 
GMRx2 at equivalent doses. 
 
 TRIAL DESIGN 
An international randomized, double-blind, active-controlled, parallel-group trial with a 4-week pre-
randomization single-blind, active run-in, a 12-week randomized treatment period and a 4-week safety follow-
up period. The overall trial design is shown in Figure 2. 
 
Figure 2: Trial design summary 
 
7.1. Trial Design Rationale 
This trial is designed to investigate the efficacy and safety of GMRx2 for reducing BP in adult participants with 
high BP compared to dual combinations. The run-in period will assess participant adherence to trial medication 
and trial procedures, hence maximizing chances of complete follow-up and data collection. The double-blind 
periods will assess the efficacy and safety of GMRx2 Dose 2 and GMRx2 Dose 3, sequentially, compared to the 
corresponding three possible dual combinations of the component drugs. This will enable assessment of the 
contribution of each of the component drugs of GMRx2. The duration of 6 weeks for each double-blind period 
will enable demonstration of the maximum effects of each regimen. Double-blinding will prevent performance 
bias for investigators, study staff and trial participants. The safety follow-up period will assess safety after 4 
weeks of the discontinuation of the randomized trial medication.  
7.2. Sub-studies 
Participants will be invited to provide venous blood specimens at the Week 12 visit for use in planned substudy 
analyses related to measurement of drug metabolite levels. The samples will be immediately processed and 

GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 18 of 49 
stored at −80°C ± 10°C and shipped during or at the end of the study to a central laboratory for storage until 
analyses have been completed.   
 METHODS: PARTICIPANTS, INTERVENTION & OUTCOMES 
8.1. Trial Setting & Participant Recruitment 
Trial participants will be recruited from clinics or hospital-based out-patient departments or primary care 
centers that provide hypertension care in the participating countries. Based on the recruitment rate and trial 
timelines, other modes of recruitment that could be used include community resources particularly to target 
women and minority/under-served populations (also to ensure adequate representation of these groups), 
referrals from other hospitals/clinics and trial recruitment advertisement in the form of posters, flyers, via 
social media, etc. 
8.2. Participant Eligibility 
The guiding principle of participant eligibility is individuals with hypertension who could be appropriately 
treated with triple or dual combinations, with the component drugs, each at half or standard doses. 
  Inclusion Criteria 
At screening visit 
1. Provided signed consent to participate in the trial. 
2. Adult of age ≥18 years. 
3. Clinic attended automated seated mean SBP (average of 3 measurements): 
a. 140-179 mmHg on 0 BP-lowering drugs, or 
b. 130-170 mmHg on 1 BP-lowering drug, or 
c. 120-160 mmHg on 2 BP-lowering drugs, or 
d. 110-150 mmHg on 3 BP-lowering drugs. 
 
Note: A single tablet containing 2 or 3 different BP lowering agents (i.e. a combination medication) is 
considered as 2 or 3 BP lowering drugs, respectively.  
 
At randomization visit 
1. Home seated mean SBP 110-154 mmHg in the week prior to the randomization visit.  
2. Adherence of 80-120% to run-in medication. 
3. Tolerated run-in medication. 
4. Adherence to home BP monitoring schedule: in the week before randomization, at least 6 measures 
(e.g. ≥2 sets of triplicate measures, ≥3 sets of duplicate measures) including at least 1 morning and 1 
evening each with ≥2 measures  
5. Morning is defined as any measure in the am and evening as any measure in the pm. Morning and 
evening do not have to be same day. 
 
1.  
 
 Exclusion Criteria 
At screening visit 
1. Receiving 4 or more BP-lowering drugs.  
2. Receiving any BP lowering drugs for indications other than hypertension e.g. heart failure 
3. Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test during the trial 
and up to 30 days after the discontinuation of the trial medication or breastfeeding or of childbearing 
age and not using an acceptable method of contraception (defined in the Manual of Procedures). 
Acceptable methods of birth control include Hormonal prescription oral contraceptives, contraceptive 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 19 of 49 
injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragm, 
or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization. Contraception should 
be used for at least 1 month before the screening visit and until the end of trial participation. 
4. Meets any criteria of local ethical or regulatory requirements related to severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) that would deem participation in a clinical trial unsuitable. 
5. Contraindication, including hypersensitivity (e.g. anaphylaxis or angioedema), to the active run-in 
treatment or to any of the trial medication options in the four randomized groups. 
6. Current/history of transient ischemic attack, stroke, or hypertensive encephalopathy. 
7. Current/history of acute coronary syndrome, unstable angina, myocardial infarction, percutaneous 
transluminal coronary revascularization, or coronary artery bypass graft.  
8. Current atrial fibrillation. Patients with a history of paroxysmal atrial fibrillation are potentially eligible 
as long as there has been no episode in the last 3 months, while patients with a history of persistent or 
permanent atrial fibrillation are not eligible. 
9. Current/history of New York Heart Association class III and IV congestive heart failure.   
10. Current/history of cardiomyopathy or any other cardiovascular condition of sufficient severity to 
contraindicate the trial medications or require a contraindicated medication.   
11. Current/history of a known secondary cause of hypertension, such as primary aldosteronism, renal 
artery stenosis, pheochromocytoma, or Cushing's syndrome. 
12. Current/history of severe uncontrolled diabetes (HbA1c > 11.0% (> 97 mmol/mol)) within last three 
months. 
13. Current/history of end-stage renal disease or anuria; or current estimated glomerular filtration rate 
(eGFR) <60 ml/min/1.73m2 
14. Current electrolyte levels that would be regarded as contraindications for any of the potential treatment 
arms e.g.  serum sodium <132mmol/l or >148 mmol/l or serum potassium <3.1 mmol/l or >5.6mmol/l.  
15. Current/history of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the 
upper limit of normal range within 6 months. 
16. Current concomitant illness or physical impairment or mental condition that in the judgment of the 
investigator could interfere with the effective conduct of the trial or constitute a significant risk to the 
participants’ safety or well-being.  
17. Arm circumference that is too large or too small for available cuffs to allow accurate measurement of 
BP. Upper limit is 55cm in all countries, while lower limit is 15cm or 24cm in different countries, 
depending on available cuff sizes. 
18. Currently taking or might need during the trial, a concomitant treatment which is known to interact with 
one or more of the trial medications: digoxin, lithium, diabetics receiving aliskiren, moderate and strong 
CYP3A4 inhibitors (e.g. ritonavir, ketoconazole, diltiazem], simvastatin >20 mg/day, 
immunosuppressants. 
19. Might need treatment with drugs that are prohibited during the trial:  other antihypertensive drugs, 
endothelin receptor antagonists, neprilysin inhibitors, or other drugs that may affect BP  (see Appendix 
5). 
20. Current surgical or medical condition that might significantly alter the absorption, distribution, 
metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. 
gastrectomy, lap band, or bowel resection) or acute flare of inflammatory bowel disease within one 
year. 
21. Individuals working >2 nightshifts per week. 
22. Participated in any investigational drug or device trial within the previous 30 days.  This does not include 
participants in the extended safety follow-up portion of a trial.  
23. History of alcohol or drug abuse within 12 months. 
 
At randomization visit      
1. Unable to adhere to the trial procedures during the run-in treatment period. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 20 of 49 
2. Any of the following which in the investigator’s judgment may compromise the safety of the participant 
if randomized to the trial medications: 
a. High or low clinic BP levels even in the light of the values for home BP that are available for that 
participant. The exact levels of BP are not specified, since there is clinical uncertainty as to the 
relevance of BP levels which are high or low in clinic only; for example, the clinical relevance of 
‘whitecoat hypertension’ is uncertain. 
b. High or low home diastolic BP (DBP) levels. The exact levels of DBP is not specified, reflecting 
clinical uncertainty of the implications of isolated diastolic hypertension. However, home DBP 
values of >99 mmHg may typically be considered as requiring treatment intensification, and such 
participants would not be suitable for randomization. 
c. Any abnormal laboratory value which in the judgment of the investigator could interfere with the 
effective conduct of the trial or constitutes a significant risk to the participants’ well-being.  
d. Fulfilling any of the exclusion criteria mentioned for the screening visit, when verified again at 
randomization visit.  
 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 21 of 49 
8.3. Trial Schema 
Figure 3: Trial schema 
  
8.4. Intervention 
  Single-Blind Active Run-In Period 
During the screening visit, enrolled participants will be asked to discontinue all current BP-lowering drug(s) if 
applicable and enter a single-blind active run-in period for 4 weeks with GMRx2 dose version 2. Participants 
will be advised to take the run-in capsule once daily in the morning at approximately the same time each day. 
For days on which BP is being measured, the run-in capsule should be taken directly after the morning home 
BP measurement. 
   Double-Blind Treatment Period 
The 4-week single-blind active run-in will be followed by a 12-week double-blind period with randomization 
to one of the following four treatment groups: 

GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 23 of 49 
trial medication that the participant was receiving between Weeks 0 and 6. There is no need to unblind trial 
medication in this situation. Consideration should also be given to restarting scheduled medication 
subsequently, if benefits of restarting outweigh the risks as per the medical condition of the participant. If a 
participant discontinues medication at his/her own initiative, the reason should be investigated. If medically 
appropriate, consideration should be given to restarting study medication. 
8.8. Early Permanent Discontinuation of Trial Medication 
Discontinuation of trial medication occurs when a randomized participant permanently ceases taking the trial 
medication regardless of the circumstances, before the Week 12 visit and must be reported immediately to 
the CRO and recorded in the study database. In the case of early discontinuation of a participant from the trial 
medication, the reason for discontinuation will be recorded and immediately reported in the IBM Clinical 
Development trial database.  
 
Early permanent discontinuation of trial medication may happen for the following reasons: 
 By the participant himself/herself for any reason. 
 By the investigator at the request of the participant for any reason. 
 By the investigator if the participant’s safety or wellbeing is or will be compromised by continued trial 
medication, including if the participant becomes pregnant  
 The trial is terminated (e.g. if in the opinion of the DSMB interim data indicate that it might not be 
justifiable to continue the trial, the SC may terminate the trial).  
 
In general, unblinding is not required in these situations, see Section 11.4.2 Unblinding of Trial Medication in 
a Clinical Emergency. 
 
If necessary, the investigator will arrange for an alternative treatment to be prescribed by the treating 
physician. Participants with early permanent discontinuation of the trial medication are not considered 
withdrawn from the trial and should continue their participation in the trial as normal, completing all trial visits 
and assessments until the final trial visit at Week 16. For withdrawal from trial participation, see Section 13, 
page 34. 
8.9. Post-Trial Medication  
At the Week 12 visit , the investigator or responsible clinician will provide appropriate continued medical 
care to participants in line with local guidelines/practice.  
 OUTCOMES 
9.1. Efficacy Outcomes 
  Primary 
 Difference in change in home seated mean SBP from randomization to Week 12. 
  Secondary 
 Difference in change in clinic seated mean SBP from randomization to Week 12. 
 Difference in change in clinic seated mean SBP from randomization to Week 6. 
 Difference in change in clinic seated mean DBP from randomization to Week 12. 
 Difference in change in clinic seated mean DBP from randomization to Week 6. 
 Percentage of participants with clinic seated mean SBP <140 and DBP <90 mmHg at Week 12. 
 Percentage of participants with clinic seated mean SBP <140 and DBP <90 mmHg at Week 6. 
 Percentage of participants with clinic seated mean SBP <130 and DBP <80 mmHg at Week 12. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 24 of 49 
 Percentage of participants with clinic seated mean SBP <130 and DBP <80 mmHg at Week 6. 
 Difference in change in home seated mean SBP from randomization to Week 6. 
 Difference in change in home seated mean DBP from randomization to Week 12. 
 Difference in change in home seated mean DBP from randomization to Week 6. 
 Difference in change in trough home seated mean SBP from randomization to week 12 
 Difference in change in trough home seated mean SBP from randomization to Week 6 
 Percentage of participants with home seated mean SBP <135 and DBP <85 mmHg at Week 12. 
 Percentage of participants with home seated mean SBP <135 and DBP <85 mmHg at Week 6. 
 Percentage of participants with home seated mean SBP <130 and DBP <80 mmHg at Week 12. 
 Percentage of participants with home seated mean SBP <130 and DBP <80 mmHg at Week 6.  
9.2. Safety Outcomes 
 Primary 
 Percentage of participants discontinued trial medication due to AE/SAE from randomization to Week 
12. 
 Secondary 
 Percentage of participants discontinued trial medication due to AE/SAE from randomization to Week 
6. 
 Percentage of participants with an SAE from randomization to Week 12. 
 Percentage of participants with SAE from randomization to Week 6. 
 Percentage of participants with symptomatic hypotension from randomization to Week 12. 
 Percentage of participants with symptomatic hypotension from randomization to Week 6. 
 Percentage of participants with serum sodium concentration below 135 mmol/l at Week 12. 
 Percentage of participants with serum sodium concentration below 135 mmol/l at Week 6. 
 Percentage of participants with serum sodium concentration above 145 mmol/l at Week 12. 
 Percentage of participants with serum sodium concentration above 145 mmol/l at Week 6. 
 Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 12. 
 Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 6. 
 Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 12. 
 Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 6. 
 Percentage of participants with serum sodium <135mmol/l or >145 mmol/l, and/or serum potassium 
<3.5 mmol/l or >5.5mmol/l at week 6.  
 Percentage of participants with serum sodium <135mmol/l or >145 mmol/l, and/or serum potassium 
<3.5 mmol/l or >5.5mmol/l at week 12.  
 Percentage of participants with eGFR drop of over 30% from randomization to Week 12. 
 Percentage of participants with eGFR drop of over 30% from randomization to Week 6. 
 Percentage of participants with orthostatic hypotension at Week 6, 
 Percentage of participants with orthostatic hypotension at Week 12 
 Percentage of participants with orthostatic hypertension at Week 6, 
 Percentage of participants with orthostatic hypertension at Week 12 
 
 Descriptive Safety Outcomes 
In addition, descriptive safety data will be reported on: 
 Percentage of participants discontinued trial medication due to AE/SAE during the active run-in period 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 25 of 49 
 All SAEs, by severity and by System Organ Class (SOC) criteria during the run-in period, by trial 
medication group during the randomized period, and safety follow-up period.  
  
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 28 of 49 
explanation about the requirement to fast for blood sample collection at the screening visit. They will be given 
the opportunity to ask questions about the fasting process and will be receive full answers from the trial site 
staff. Verbal consent can be obtained by telephone and must be clearly documented in participants’ trial 
records. Where feasible and approved by IRB/IEC, the verbal consent process may also be adopted to facilitate 
collection of screening bloods prior to the screening visit. Prior to performing all other trial procedures 
participants must provide written informed consent. 
  Assessment of Participant Eligibility 
Each potential participant will be assessed for eligibility to participate in the trial as per the protocol-defined 
eligibility criteria. Responsible site investigator(s) will ensure that only eligible participants are enrolled in the 
run-in treatment period and the randomized treatment period of the trial.  
  Medical History 
A detailed medical history will be collected at the screening visit. This will be based on participant medical 
records and/or self/carer-report. Participant’s medical condition will be re-assessed before randomization to 
confirm eligibility for randomization. 
  Physical Examination 
The physical examination includes elements of a systems-based examination deemed necessary for the safety 
of participants by the site investigator. Elements of the examination may vary from participant to participant 
depending upon the health status and symptoms reported, the time and type of visit (initial, follow-up). The 
physical examination will not be standardized, and information will be captured in the source documents for 
each participant.  
   Anthropometric Measurements 
Height and weight will be measured as per the prevailing practice at the trial sites, and these measurements 
will be used for calculating the body mass index.  
  Clinic BP Measurement 
Clinic BP will be measured in the seated position during all scheduled trial visits using a standard procedure 
(See Appendix 2). To allow flexibility in site visit scheduling and maintenance of participants typical time of 
taking trial medication, and since all morning home BP measures are to be taken before the next dose of the 
trial medication, clinic measures are not required to be conducted at trough. 
   Home BP Measurement 
For the days on which home BP is measured, BP measurements should be at the same time in the morning and 
evening on each measurement day during the following time ranges:  
1. morning (ideally between 06:00-10:00 hours) – prior to taking trial medication;  
2. evening (ideally between 18:00-22:00 hours).  
Participants should aim to have at least 6 hours interval between the morning and evening measurements.  
In the week before the Randomization, Week 6 and Week 12 trial visits, BP measurements should be taken on 
the 4 days immediately prior to the day of the day of the on-site trial visit. In other weeks, measurements 
should ideally be performed on a single set day. Each home BP measurement should be done as a triplicate i.e., three individual measurements,, following the protocol outlined in Appendix 3, page 42. Telemonitored BP 
values will be monitored for adherence with measurement schedules and high values (as noted in Section 8.6, 
page 22), with reporting to the clinic and for medical management as needed. 
 
Participants eligible for run-in medication will be issued with a home BP monitor at the screening visit and will 
be asked to bring it with them to the randomization visit. If they continue to randomization, they will continue 
to use the same home BP monitor. 
   Electrocardiogram 
A 12-lead electrocardiogram (ECG) will be obtained at the screening visit to determine the occurrence of silent 
myocardial infarction, atrial fibrillation, and left ventricular hypertrophy. Site investigators will review ECG 
reports and comment as either normal or abnormal, and if latter whether clinically significant.     
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 29 of 49 
  Laboratory Investigations 
The 2017 ACC/AHA-recommended laboratory investigations will be performed at the screening visit. These 
investigations will help in ascertaining participant safety and eligibility for trial participation. For investigations 
that are to be done in the fasting state, participants will be informed beforehand to fast for blood sample 
collection. Protocol-required laboratory investigations will be performed at a local laboratory in each 
participating country following the usual standard procedures of sample collection, analysis, and reporting.  
Optional substudy blood samples will be immediately processed and stored at −80°C ± 10°C and shipped during 
or at the end of the study for storage and future analyses.  
  Allocation of Trial Medication  
During the single-blind run-in period (Week -4 to Week -1 inclusive) all participants will be allocated GMRx2 
dose version 2. During the double-blind period (Week 1 to Week 12 inclusive) all participants will be allocated 
GMRx2 or one of the three dual combinations as per the randomization scheme. Neither the site staff nor the 
participants will have foreknowledge of the treatment allocation at randomization. After the completion of the 
double-blind treatment period at Week 12, participants will be switched to non-trial medication as per local 
guidelines/practice. 
  Dispensation of Trial Medication 
Starting at the screening visit (Week -4), participants will receive sufficient quantities of the trial medication 
until the next scheduled trial visit. In the case of lost/damaged dispensed treatment, participants will be asked 
to notify the site immediately and replacement treatment will be dispensed by the site. In circumstances where 
a participant is unable to return to the site to collect replacement trial medication between two scheduled trial 
visits, trial medication delivery will be arranged to the participant’s location. Delivery of trial medication to 
participant’s location may also occur in other circumstances and where feasible e.g. if blood test results are not 
available during the screening and randomization visits and randomization and/ or dispensing is delayed or due 
to pandemic restrictions. Sites will maintain accurate and up-to-date records of all trial medication dispensation 
to participants. Such records must be available for inspection at all times. 
 Returning of Trial Medication  
Trial participants will return all unused trial medication to the sites during scheduled trial visits (or in between 
in some circumstances – e.g. discontinuation of treatment). Sites will collect all the returned trial medication 
and keep an accurate record, to be available for inspection at all times.  
 Concomitant Treatments 
Starting at the screening visit, during all scheduled and unscheduled visits until the end of participation, the 
investigator/site will review participant concomitant treatments and update the relevant section in source 
documents and electronic case report form (eCRF) keeping in view the trial allowed and prohibited concomitant 
treatments. Non-trial BP lowering medication must be ceased prior to starting trial medication and 
documented in the eCRF. Prescription of non-trial BP-lowering drugs will only be allowed as noted in Section 
8.6, page 22. Treatment with other drugs that do not affect BP significantly will be unrestricted and will be at 
the discretion of the treating physician. For the prescription of concomitant treatments, contraindications and 
drug-drug interactions should be taken into consideration as per the regulatory-approved prescribing 
information of drug prescribed. All other medical care should be delivered according to local 
guidelines/standards by the treating physician.  
10.3. Visit Details 
 Pre-Screening Visit (As Required) 
 Can be conducted by telephone. 
 Assess potential participant’s interest for participation and eligibility for the trial. 
 Discuss the trial with the participant, including using the PISCF, and obtain signed informed consent. 
Participants may be provided time to consider their participation, with a follow-up visit arranged as 
needed. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 30 of 49 
 Consider modifying current treatments to facilitate trial eligibility, if clinically appropriate and 
considered safe. Informed consent must be obtained before the modification of medication(s). If 
medications are altered, a period of at least 14 days is required between alteration of BP treatment(s) 
and trial enrolment. 
 If locally preferred and/or feasible, Screening Visit blood tests can be pre-arranged following informed 
consent. 
 Screening Visit 
 Assess the potential participant’s interest and eligibility for the trial. 
 Discuss the trial with the participant, including using the PISCF, and obtain signed informed consent. 
This can also be done before the screening visit. The participant can be given the opportunity to 
consider information and return within the time window for randomization. 
 Collect demographic information. 
 Collect information on medical history, perform a physical examination.  
 Measure height and weight. 
 Measure BP and pulse. 
 Perform 12-lead ECG. 
 Collect blood samples for pre-run-in assessment, including pregnancy, if applicable . If pre run-in blood 
tests (sodium, potassium, chloride, creatinine, liver function) have been conducted within the past 3 
months, these results can be utilized to assess suitability for run-in. Results must be reviewed and 
eligibility confirmed prior to enrolment into the study and run-in medication start. If laboratory results 
are not available on the day of the screening visit, the participant may be required to return to the 
clinic for collection of run-in medication and the home BP monitor as soon as results become available 
and eligibility has been confirmed. Alternately, if feasible according to local practice and if the 
participant consents, the home BP monitor and run-in medication may be delivered by courier to the 
participant’s home. A flexible approach in accordance with local logistics and practice is permitted, so 
long as within local IRC/EC approval. 
 In case of a delayed start to run-in medication, a run-in that is ideally 28 days and at least 21 days is 
still required and therefore the randomization visit may need to be delayed accordingly.  
 Arrange laboratory investigations required to be reviewed before randomization, which includes 
fasting blood sample. This must be done during run-in while receiving run-in treatment. 
 Assess eligibility as per the trial inclusion and exclusion criteria. 
 Demonstrate home BP measurement and dispense home BP monitor (record serial number) to 
participant. 
 Discontinue non-trial BP lowering medications. 
 Dispense run-in medication.  
 Re-Screening 
Participants can be re-screened up to three times in total during the recruitment period. Participants not 
meeting the eligibility criteria at Pre-Screening or Screening Visit can be re-screened if the reason for non-
eligibility was transient (e.g. a short-term illness, abnormal laboratory finding, etc.), or if eligibility is expected 
to change (e.g. due to an alteration in BP regimen), or a remediable non-medical issue prevented completion 
of run-in (eg. BP machine malfunction).  However, participants cannot be re-screened if they were intolerant 
of the run-in medication, if they required add-on medication during run-in or if valid home BP measurements 
did not meet criteria for entering run-in . Before re-screening, a new consent must be signed if more than 2 
months have elapsed since signing the consent the first time. All eligibility criteria must be re-assessed on re-
screening. Trial-specific laboratory investigations results available from within 30 days of the date of re-
screening may be used to assess eligibility for trial participation. 
 Extended Run-In 
The run-in period can be extended by up to 1 week if needed for reasons such as technical issues with the BP 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 31 of 49 
machine or measurement protocol or administrative issues, such as a delay in receiving test results. However, 
the run-in period cannot be extended if the treatment was not tolerated or if valid home BP measurements did 
not meet criteria for randomization.  If the run-in is extended, participants should measure home BP in the 4 
days prior to the new Randomization Visit date. 
 Pre-Randomization visit  
 Collect blood and urine samples for which the results should be available prior to Randomization (see 
Table 5. 
 
 Randomization  Visit  
 Measure BP and pulse. 
 Record any AESIs or SAEs that have occurred since the screening visit. 
 Collect unused run-in medication. 
 Assess adherence to run-in medication. 
 Assess adherence to home BP monitoring schedule. 
 Record all medication currently being taken by the participant. 
 Review home BP measurement technique. 
 Assess eligibility as per the trial inclusion and exclusion criteria. 
 Review pre-randomization laboratory results.* 
 Confirm that participant is suitable to be randomized.* 
 If relevant, discuss with female participants of child-bearing potential the need to conduct home 
pregnancy tests every 4 weeks during the treatment period and provide pregnancy test kits. (Applies 
in some jurisdictions including Czech Republic, Poland and South Korea).  
 Randomize participant. 
 Dispense treatment according to the allocated kit number selected by IBM database. 
 For participants not suitable to continue, collect home BP monitor. 
*If laboratory results are not available for review prior to or on the same day end of run-in /randomization visit, 
randomization must be delayed until the results are available and eligibility has been confirmed. If eligible, the 
participant will either be required to return to the clinic for the collection of randomized treatment,  or 
alternatively, if feasible according to local practice and if the participant consents, the randomized medication 
may be delivered to by courier to the participant’s home. Run-in treatment should be continued until 
randomization, If randomization is delayed. 
 Week 6 Visit 
 Measure BP and pulse. 
 Record AESIs or SAEs since the previous visit. 
 Collect blood for measurement of electrolytes, creatinine, and eGFR 
 Review all medications being taken by the participant.  
 Collect unused trial medication. 
 Dispense treatment according to the allocated kit number selected by IBM database. 
 Week 12 Visit  
All participants  
 Measure BP and pulse. 
 Record AESIs or SAEs since the previous visit. 
 Review all medications being taken by the participant and update medications.  
 Collect unused trial medication and review medication adherence. 
 Collect the Week 12 fasting blood and urine samples for laboratory investigations. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 32 of 49 
 Collect blood sample for storage for substudy (if applicable) 
 Week 16 visit (End of Trial Visit) 
 Contact participant by telephone. 
 Record AESIs or SAEs since the previous visit. 
 Review all medications being taken by the participant and update medications 
 Explain that the trial follow-up is now completed and thank participant 
 METHODS: ASSIGNMENT OF INTERVENTION 
11.1. Allocation Sequence Generation 
A central, computer-based randomization sequence will be generated, stratified by trial site.  
11.2. Allocation Concealment 
Randomization sequence will be incorporated into an online electronic data capture (EDC) application by a 
statistician. Neither the Investigators nor site staff will have access to the randomization sequence.  
Participants meeting eligibility for randomization, can be randomized in the online EDC. The EDC application 
will generate the randomization record with the participant identification number and date and time. 
11.3. Blinding (Masking) 
Neither the site staff, including those measuring the outcomes nor the participants will be aware of the 
treatment allocated since all trial medication will be provided in identical capsules. Access to information on 
allocated treatment will be restricted. Breaking of treatment code (unblinding) will be restricted to situations 
that necessitate ascertainment of type of medication for a given participant to provide appropriate care. To 
protect blinding, all medications will have an identical appearance.  None of the trial committees will have 
access to the code list of allocated treatments.   
11.4. Unblinding 
 Unblinding of Trial Medication for Expedited Safety Reporting  
Where country regulatory safety reporting requirements mandate the reporting of unblinded data, treatment 
assignment will be unblinded before they are reported to the Competent Authorities and IRB/IEC in accordance 
with the local safety reporting requirements. The trial medication assignment will only be made available to 
the relevant Competent Authorities and IRB/IEC and not be communicated to participants, investigators, or the 
CRO staff.  
  Unblinding of Trial Medication in a Clinical Emergency 
In general, unblinding will only be required in certain specific circumstances which are expected to be very rare. 
If a contraindication to trial medication develops after randomization, the trial medication should simply be 
stopped and usual standard care given. Unblinding should be done only in those rare cases when the clinician 
believes that clinical management depends importantly upon knowledge of which treatment the participant 
received. In these cases when urgent unblinding is considered necessary, a 24-hour access service will be 
available. An unblinding report form should then be completed by the investigator.  
 METHODS: DATA COLLECTION, MANAGEMENT & STATISTICAL ANALYSIS 
12.1. Data Collection 
The investigator will be responsible for ensuring the accuracy, completeness, and timeliness of the data 
collected for the trial. All source data should be legible and complete to ensure accurate interpretation.  
 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 33 of 49 
The trial will use an eCRF for data collection. Trial site staff will be trained on eCRF. Delegated site staff provided 
with the access (with username, password) will enter data in the eCRF regularly according to instructions for 
completion and any data queries will be resolved promptly. Data entered in eCRF should be consistent with the 
source data. For home BP values, the home BP machine is the data originator and the eCRF is regarded as the 
source record.60  For BP values measured in clinic in which a paper transcription step is used, then the paper 
documentation should be retained and made available for inspection.60 The investigator will sign each 
participant’s eCRF confirming and certifying that the data entered is accurate and complete. All data collected 
in the eCRF will be securely stored with access restricted to representatives authorized for data management, 
and data analysis at the end of the trial.  
12.2. Data Management 
All data entry will be completed via the secure web-based data management system, IBM Clinical Development. 
Data entry will be performed at the participating sites by authorized site staff who have completed training and 
been given appropriate role-based access to the system. Data logic and consistency checks will be programmed 
into the data entry forms so that data entry errors can be caught real time and queries auto-generated.  Manual 
queries may also be generated and listings will be run to perform manual data checks which cannot be 
programmed. Authorized electronic signatures will be used to lock completed data entry forms once all data 
queries have been resolved within the system. Data entry and all subsequent changes or deletions will be 
captured in an accessible audit trail. Coding will be centrally performed either automatically via the IBM coding 
module or manually. Data will be stored and backed up on the IBM’s cloud servers in the USA. 
12.3. Sample Size & Power Calculation 
A sample size of 1500 participants (600 in GMRx2 and 300 in each of the dual combination groups) provides 
97% power to detect a minimum difference of 3 mmHg in home seated mean SBP for each of the three 
comparisons of GMRx2 vs dual therapy, assuming a common standard deviation of 11 mmHg within each group. 
The overall power for all three comparisons will therefore be over 90%. Randomizing 1500 may necessitate at 
least 2000 participants entering the run-in treatment. A systematic review of previous trials of triple vs dual 
combination therapy demonstrated, on average, a 5.4/3.2 mmHg greater reduction in clinic BP with triple 
therapy,61 and it is anticipated that the current trial will have similar rates of drop-in and drop-out as observed 
in those trials. A systematic review comparing BP reductions from different BP measurement methods 
indicated that on average reductions in home BP were about 20% less than those seen for clinic BP.62 In three 
recent trials that utilized home BP measurement protocols very similar to those planned for this trial, the 
average SD of change in home SBP was 11 mmHg.21,63,64 
12.4. Statistical Methods 
All analyses will be performed on an intention-to-treat basis. Baseline characteristics by the group will be 
compared using descriptive analyses. The primary outcome of difference in change in home SBP from baseline 
to Week 12 will be analyzed using a mixed model for repeated measures with baseline BP, visit, treatment 
group, and visit by treatment group interaction as a fixed effect and accounting for correlation within 
participant and clustering at the site level. Other continuous outcomes of difference in change in BP will also 
be analyzed as the primary outcome. All continuous outcomes will be reported along with 95% CI and the 
corresponding p-value. The percentage of participants achieving target BP at Week 6 and Week 12 will be 
summarized descriptively and analyzed using generalized estimating equations with the visit, treatment group, 
and visit by treatment group interaction as a fixed effect and accounting for correlation within participant and 
clustering at the site level. Percentages by treatment groups with 95% CI will be presented along with the 
associated estimated odds ratio and its corresponding p-value. Other binary outcomes of efficacy and safety 
will be analyzed as the percentage of participants achieving target BP. The primary analysis dataset will be 
locked after the last participant has reached the 16 week follow-up visit. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 34 of 49 
 WITHDRAWAL FROM TRIAL PARTICIPATION 
Participants will be informed at the time of consenting and enrolment that; they are free to withdraw from the 
trial at any time and for any reason without influencing any aspect of their usual medical care. If a participant 
wishes to withdraw from the study prior to completion and explicitly revokes consent or if the trial investigator 
decides it is in the best interest of the participant to withdraw from the trial, every effort should be made for 
the participant to complete a final follow-up assessment to record BP, AESI and SAEs and collect all unused trial 
medication. Data collected up to the point of withdrawal will be included in trial analyses unless the participant 
expressly requests their data to be excluded. 
 TRIAL MEDICATION MANAGEMENT 
14.1. Manufacturing 
The formulation development and manufacturing of GMRx2 will be conducted as per Good Manufacturing 
Practice and in accordance with the applicable regulatory requirements. 
14.2. Packaging, Labelling, Distribution & Storage 
Packaging, labeling, quality release, storage, and distribution of the trial medication to the local country depot 
or directly to participating sites will be conducted as per the local regulatory and set-up requirements. All 
shipments will be temperature-monitored, and where required, temperature-controlled shipments will be 
conducted. The CRO will keep accurate records of trial medication supplies to trial sites. At each trial site, the 
Investigator will be responsible to store and maintain accurate records of trial medication and report to the 
CRO. Trial sites will store trial medication as per the labeled instructions and will instruct the trial participants 
accordingly.  
14.3. Return & Destruction 
At the end of the trial, following the accountability of the returned/unused trial medication, and on the 
authorization of the ACC, trial medication will be destroyed on-site or returned to the depot for destruction. 
Once destroyed, a destruction certificate or record will be provided to the site. 
 MANAGING INTERRUPTION OF STUDY MATERIAL SUPPLY TO TRIAL CENTRES 
Supply chain-related interruptions of study materials to trial centres may occur, especially in the context of a 
pandemic, in which case the following strategies should be adopted. If study BP machines are not available at 
the centre, participants should not be entered into run-in, but asked to return when BP machines are available, 
which may necessitate re-screening. If study treatment for any trial phase (Run-in/Period 1, Period 2 or Period 
3 as in  Figure 2) is not available at the centre or not certain to arrive in adequate time, the participant should 
delay the start of Run-in, which may necessitate rescreening. If a participant is on Run-in/Period 1 and Period 
2 and/or 3 study treatment is not available or not certain to arrive in adequate time, then randomization should 
be delayed, which may necessitate extending or repeating run-in. If a participant is randomised and receiving 
Period 2 study treatment (see Figure 2, ie. could be receiving GMRx2-dose2, telmisartan 20mg/amlodipine 
2.5mg, telmisartan 20mg/indapamide 1.25mg, or amlodipine 2.5mg/indapamide 1.25mg) but Period 3 study 
treatment is not available, then at the week 6 study visit participants should switch to open-label telmisartan 
40mg and amlodipine 5mg. This open-label treatment should be continued until Period 3 study treatment is 
available at the centre, at which time a repeat clinic visit should be arranged and Period 3 treatment instituted. 
Home BP monitoring should be continued throughout and any additional tests instituted as required to ensure 
patient safety. There is no need to unblind.  The final clinic visit of the randomised phase should be rescheduled 
for 6 weeks after the new start date of the Period 3 study treatment. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 35 of 49 
  MONITORING 
16.1. Data & Safety Monitoring Board 
An independent DSMB will monitor the trial data and advise the SC on the continuing safety of trial participants 
and those yet to be recruited to the trial, as well as the continuing validity and scientific merit of the trial.  
16.2. Data Monitoring 
In addition to pre-programmed edit checks in the eCRF, regular remote data monitoring will be conducted by 
the responsible CRO and designated monitors for confirmation of participant eligibility, identification of missing 
data, data consistency, and general data quality checks.  Automated queries may be generated via 
programming in the eCRF and can also be manually generated by monitoring staff. On-site monitoring visits will 
also be conducted to review source documents and to resolve any issues at the site. Full details of monitoring 
activities will be described in the Trial Monitoring Plan. The investigator should allow the monitors, the 
persons responsible for the audit, the representatives of the sponsor, the IRB/IEC, and of the Regulatory 
Authorities to have direct access to source data/documents. The CRO will also undertake regular remote 
monitoring of data. 
 SAFETY 
17.1. Safety Definitions  
 Adverse Event 
An AE is any untoward medical occurrence in a participant administered a pharmaceutical investigational 
medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can, 
therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a medicinal (investigational) product, whether or not related to 
the medicinal (investigational) product. Only AEs that are defined as AESIs will be collected. 
  Adverse Event of Special Interest 
The following AEs are considered AESIs and will be collected: 
 Symptomatic hypotension: Dizziness or any other symptom or event possibly related to hypotension 
 Abnormal laboratory findings of sodium, potassium, uric acid, glucose, lipids, creatinine or eGFR 
 Headache 
 Peripheral edema 
 Any other symptom or laboratory abnormality that led to permanent discontinuation of trial 
medication. 
 Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose; results in death, is life-threatening, requires 
inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant 
disability/incapacity, or is a congenital anomaly/birth defect. Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention 
to prevent one of the outcomes listed in this definition. Hospitalization means the participant has been formally 
admitted to a hospital for medical reasons. It does not include a presentation at a casualty or emergency room. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen during the study is not 
considered an SAE or AE. Complications that occur during hospitalization are AEs. If a complication prolongs 
hospitalization or otherwise meets seriousness criteria, the event is an SAE. 
 Intensity/Severity of an AESI/SAE 
All AESI/SAEs will be graded as mild, moderate, or severe by the investigator based on her/his medical judgment 
and the following guidance: 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 36 of 49 
 Mild:  asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated. 
 Moderate:  limiting age-appropriate instrumental activities of daily living (e.g. preparing meals, 
shopping for groceries or clothes, using the telephone). Minimal, local or non-invasive intervention 
indicated. 
 Severe:  Medically-significant but not immediately life-threatening; disabling; limiting self-care 
activities of daily living (e.g. bathing, dressing and undressing, feeding self); hospitalization or 
prolongation of hospitalization indicated. 
 Relationship to the Trial Medication 
All AESIs/SAEs will be assessed for causal relationship to the study medication by the investigator and reported 
as either definitely, probably, possibly, unlikely related, or not related. 
 Serious Unexpected Suspected Adverse Reaction 
A suspected unexpected serious adverse reaction (SUSAR) is a suspected adverse reaction related to an 
investigational medicinal product that is both unexpected and serious. An SAE will be considered unexpected 
if the nature, severity, or frequency of the event is not consistent with the information previously described for 
the trial medication in the Investigator Brochure (IB). 
17.2. Safety Reporting 
 AESI/SAE Data Collection & Follow-Up Period 
AESI/SAE data will be collected and followed-up from the time signed informed consent is obtained and up to 
the Week 16 EOT visit for the double-blind period.    Follow-up information on ongoing AESIs/SAEs obtained 
after the participant’s respective EOT visit (as applies) will not be collected in the eCRF but all attempts will 
made to follow-up SAEs/AESIs until they have resolved or stablised. 
 Trial Investigator Responsibilities in Reporting AESIs/SAEs 
Regardless of the suspected causality, every AESI/SAE must be reported by the site investigators as per the 
local regulatory and ethical requirements. All SAEs should be reported by completing the paper (Council for 
International Organizations of Medical Sciences [CIOMS] or relevant form) and eCRF SAE Form. The reports 
should identify participants by unique identification numbers assigned to the trial participants. SAEs should 
be promptly reported to the concerned parties and followed-up until resolution as per the local ethical and 
regulatory requirements. The Investigator should supply additional information (e.g. laboratory results, 
specialist/hospital letters, and autopsy results, etc.) if required by the CRO. Investigators are responsible for 
assessing if an AE meets the criteria for reporting as serious, the intensity of the event, and the relationship of 
the event with the trial medication. 
 Reporting of AESIs & SAEs 
At each trial scheduled visit and unscheduled visits during the trial, site staff will ask participants about the 
incidence of any AESIs or SAEs since the previous visit. Other AEs will not be recorded since these drugs are 
well-known and established with widespread use. Site staff may also become aware of the incidence of AEs 
during a phone call with participants. All SAEs that site staff becomes aware of from the time informed consent 
is obtained until 30 days after discontinuation of the trial medication must be recorded. The following 
information will be collected for each AESI and SAE: event name, date of onset, severity, a possible cause of 
the event, relationship to trial medication, action taken regarding the trial medication, treatment given to 
manage the event (if applicable), the outcome of event, and date of resolution (if applicable). 
 
An increase in the severity of a previously reported AESI or SAE during the trial will be reported as a new AESI 
or SAE with higher severity. A decrease in the severity of a previously reported AESI or SAE during the trial, will 
not require changes to the reported severity. Worsening of a condition, recurrent episodes, and further 
complications if any are to be reported as a follow-up of the original event. 
 
All SAEs will be reported by the site staff to the sponsor via the eCRF within 24-hours of first becoming aware 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 37 of 49 
of the event. Additional information will be collected including, seriousness criteria, hospitalization date and 
discharge (if applicable), and procedures performed (if applicable).   
 Reporting of SUSARs 
The Medical Monitor assigned by George Clinical Safety will assess all suspected serious adverse reactions in 
order to determine expectedness in accordance with the known adverse effects of each investigational drug as 
listed in the IB.  If a suspected serious adverse reaction is determined to be unexpected i.e. a SUSAR, the CRO 
will report to the applicable regulatory authorities within the required timelines. Follow-up reports will be 
generated in accordance with applicable regulatory requirements. Reports will also be provided to the 
overseeing IRB/IEC and Investigators as per country requirements. 
 Reporting of Pregnancy 
Any occurrence of pregnancy in a trial participant during the trial from the time to signing the informed consent 
until 30 days after discontinuation of the trial medication will be reported by the site staff, using a pregnancy 
form, to the trial sponsor within 24 hours of the site staff first becoming aware of it. Pregnancy will be followed 
until final resolution (i.e., delivery or early termination). Congenital abnormalities/birth defects and 
spontaneous miscarriages should be reported and handled as SAEs. Elective abortions without complications 
should not be handled as AEs. 
  Reporting of Trial Medication Use Errors or Misuse  
Reports of trial medication overdose, abuse, off-label use, misuse, or any other medication error should only 
be reported as an SAE if they are associated with suspected adverse drug reactions.  Medication error refers to 
any unintentional error in the prescribing, dispensing, or administration of a medicinal product while in the 
control of the healthcare professional or participant. All trial medication overdose, misuse and other 
medication errors associated with suspected adverse drug reactions should be routinely followed-up to ensure 
that the information is as complete as possible with regards to the symptoms, treatments, outcomes, context 
of occurrence (e.g., error in prescription, administration, dispensing, dosage, etc.). 
 ETHICAL & REGULATORY COMPLIANCE 
This trial will be designed, conducted, analyzed, and reported in compliance with ICH-GCP and local regulatory 
& ethical requirements.  
18.1. Ethical Approval 
All participating sites will submit to relevant IRB/IEC the trial protocol, PISCF and other trial-related essential 
documents, as required by the IRB/IEC, for review and approval. No sites will start the trial before the written 
approval of the IRB/IEC.  
18.2. Regulatory Approval 
Where applicable, the trial protocol, PISCF, and other trial-related essential documents will be submitted to the 
local regulatory agency as per the applicable requirement in the country. 
18.3. Confidentiality 
All documents and data relating to this trial are strictly confidential. Documents given to the investigators 
and trial sites by the CRO should not be disclosed to other parties without the written approval of the 
sponsor. The investigators/sites should maintain the confidentiality of the identification of all trial participants 
and assure the security and confidentiality of trial data and documents. 
18.4. Protocol Amendments 
Any change to the protocol will be made through a protocol amendment by the SC. The participating sites will 
submit the amendment to the relevant IRB/IEC, and the sponsor will submit to the regulatory agencies as per 
the local requirements. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 38 of 49 
18.5. Adherence to the Trial Protocol 
Investigators/sites will adhere to the trial protocol, comply with the ethical and regulatory requirements for 
the conduct of the trial. Any deviations from the protocol must not be implemented unless such a deviation is 
required to prevent/eliminate immediate harm to the trial participant(s). The investigator/site will document 
protocol deviations along with reasons and notify them to the sponsor/CRO as per the local requirements. 
 ADMINISTRATIVE SECTION 
19.1. Insurance 
The sponsor provides insurance to cover medical expenses and/or pay compensation in the event of a trial-
related injury or death to a trial participant and indemnify (with both legal and financial coverage) the 
investigator/site against claims arising from the trial, except in the case of claims that arise from malpractice 
and/or negligence, in compliance with local regulatory and ethical requirements. 
19.2. Quality Assurance 
Quality assurance will be achieved via compliance with relevant standard operating procedures, regulatory and 
ethical requirements; database design and data monitoring; training of all study staff on protocol and 
procedures; documentation of all procedures and processes; communication with stakeholders by the trial 
coordinating team; and direction and leadership of the trial by the SC. 
19.3. Trial Documents Retention 
All essential trial documents (as defined by ICH-GCP) will be archived and retained at the trial sites as long as 
to comply with the requirements of the sponsor (as specified in the agreement between the sponsor and the 
sites) and the national and international regulations (whichever is the longest period). At the end of such period, 
the investigator shall notify in writing to the sponsor of the intent to destroy all such documents. If the site 
investigator is unable to archive or cannot guarantee the archival requirements for some or all the documents, 
arrangements must be made between the investigator and the sponsor to store documents outside the site, in 
such a way that they can be accessed in the event of a regulatory inspection. These documents should not be 
destroyed without prior written approval from the sponsor. In the case of investigator wanting to assign the 
trial records to another party, or move them to another location, the sponsor must be notified in advance. 
 
For sites using an electronic system to store trial participants medical records and it cannot be confirmed that 
the electronic system is validated (as per 21 Code of Federal Regulations Part 11 or equivalent standard) or the 
sponsor representatives or the regulatory inspectors cannot be provided access to the electronic system the 
site will be requested to print the source documents needed for verification. Such printed copies should be 
numbered, stapled, and should be certified by the site investigator that they are exact copies with the same 
information as in the original source record.  
19.4. Ownership, Disclosure of Data and Dissemination policy 
The Sponsor will have full ownership of the trial data. The sponsor will register the trial and post results on 
public platforms such as ClinicalTrials.gov within the timelines stipulated by the applicable IRBs/IECs and/or 
regulatory agencies. The sponsor will develop a clinical trial report documenting results that will be submitted 
to the regulatory agencies. The SC will be primarily responsible for publications arising from the trial, which will 
be submitted for presentations at conferences and publications in journals. Authorship on publications will be 
as per the International Committee of Journal Editors criteria. Draft publications should be shared with the 
Sponsor, who will provide any comments within 30 days of receipt.   
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 40 of 49 
SOC System Organ Class 
SPC Single Pill Combination 
STRATHE STRAtegies of Treatment in Hypertension Evaluation 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TRIUMPH Triple Pill versus Usual Care Management for Patients with Mild-to-Moderate Hypertension 
USA United States of America 
 
  
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 41 of 49 
20.2. Appendix 2: Procedure for the Measurement of Clinic BP 
Procedures for clinic BP measurement are taken from AHA recommendations65 and will be performed using a 
supplied FORA D40g BP machine (also known as Medisanté BP800 machine),66,67 which is a validated, electronic, 
automatic, digital upper-arm cuff monitor,68 and the same model as that used for home BP. 
 
1. Ensure the paper clinic BP data collection form is ready with participant’s identifying information added 
and a pen is available so that BP measures can be written down directly on the form, for subsequent 
transcription to the eCRF. The paper clinic BP data collection form should be retained for monitoring. 
2. Participants should be asked to avoid caffeine, smoking and exercise for at least 30 minutes before their 
BP measurement procedure begins. This preparation is ideal not essential – if not possible, the 
measurement should still proceed 
3. Ensure the participant has emptied his/her bladder. 
4. Remove all clothing covering the location of cuff placement. Make sure to avoid rolling up sleeves, this 
may cause a (partial) tourniquet effect. 
5. Support the participant’s arm (e.g., resting on a desk). 
6. Sit with back straight and supported (e.g. on a straight-backed dining chair). 
7. Sit with feet flat on the floor and legs uncrossed. 
8. Use the correct cuff size according to arm circumference, from the Small (15 - 24cm, different cuff sizes 
available in different  countries), Medium/Large (M-L = 24 - 43cm) and Extra Large (XL = 38 - 55cm) sizes 
available, such that the bladder encircles 80-100% of the arm circumference.  
9. Position the center of the BP cuff over the upper arm brachial artery at least 1 inch above the crease of 
the elbow. 
10. Position the middle of the cuff on the participant’s upper arm at the level of the right atrium (the 
midpoint of the sternum).  
11. Once the participant is prepared, have him/her relax, sitting in a chair with feet flat on the floor and back 
supported. The participant should be seated for 5 min without talking or moving around before recording 
the first BP reading. 
12. Site staff will initiate BP measurement and will be present until all the measurements are made. 
13. Immediately after three seated BP measurements are taken, ask the participant to stand up and take an 
additional single BP measure after 1 minute of standing. 
14. Neither the participant nor the person measuring the BP should talk during the rest period or the 
measurement. 
15. A single press of the on/off button on the bottom right of the FORA D40g device will take a single measure 
(for initial left arm, right arm BP measures, at screening and re-screening visits only and for standing BP 
measures) and a single press of the AVG button on the bottom left of the device should be used for all 
seated measures. This will provide the average of three measurements, each spaced by 1 minute.  
16. At the first visit, record a single BP from each the arm. If one arm gives a reading that is more than 
10mmHg SBP higher than the other arm, then the arm with the higher measure should be used for all 
readings throughout the trial. If the SBP difference between arms is 10mmHg or less, a choice of arm 
should be made and all measures should be taken from the same arm throughout the trial for that 
participant. 
17. Ensure that the BP readings are transcribed from the paper clinic BP data collection form to the eCRF. 
 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 42 of 49 
20.3. Appendix 3: Procedure for the Measurement of Home BP 
Procedures for home BP measurement are taken from AHA recommendations65 with reference to recent trials 
and clinical use.64,69  BP measurements will be performed using a supplied FORA D40g BP  machine (also known 
as Medisanté BP800 machine), which is a validated, electronic, automatic, digital upper-arm cuff monitor, and 
the same model as that used for clinic BP.  
 
Home BP will be measured according to the following schedule: 
 on four consecutive days immediately prior to the trial visit (i.e. Weeks -1, 5, and 11), and ideally on a 
single set day of participant’s preference in other weeks.  
 in triplicate in the morning and in the evening, ideally at approximately the same time each morning 
and evening and between 06:00-10:00 hours and 18:00-22:00 hours. If these time ranges are not 
possible, measures in the am and pm are sufficient as morning and evening measures, as long as there 
is at least a 6-hour interval between the morning and evening measurements 
 the morning measurements should be immediately before the next trial medication dose 
 
Each participant will be provided a BP monitor for her/his sole use for the duration of the trial. BP readings 
will be encrypted and transferred automatically to the trial database via SIM connection. Physical recording of 
BP measurement values by participants will not be required, unless there is a technical failure in data transfer, 
in which case BP readings should be captured in the BP diaries provided and the BP monitor brought to the 
trial site for inspection. 
 
Device setting and handover to participant (site staff) 
1. Switch on the device. 
2. Ensure the supplied cuff is appropriately sized based on the arm circumference such that the bladder 
encircles 80-100% of the arm circumference. Small (15 - 24cm, available only in some countries), 
Medium/Large (M-L = 24 - 43cm) and Extra Large (XL = 38 - 55cm) sizes are available.  
3. Perform a demonstration measurement following the instructions below and ask participants if they 
have any queries.  
4. Ask participants to contact site staff if they have any questions related to home BP measurement or 
their device is not functioning properly. 
 
Information and instructions to participants 
1. Avoid smoking, caffeinated beverages or exercise within 30 minutes before the BP measurements. 
This preparation is ideal not essential – if not possible, the measurement should still proceed 
2. Urinate to empty the bladder before BP measurements. 
3. Start BP measurements after 5 minutes of seated rest.  
4. Sit with back straight and supported (e.g. on a straight-backed dining chair). 
5. Sit with feet flat on the floor and legs uncrossed. 
6. Remove all clothing covering the location of BP measurement cuff placement. 
7. Keep arm supported on a flat surface (such as a table), with the upper arm at heart level. 
8. Place the bottom of the cuff directly above the antecubital fossa (bend of the elbow). 
9. Take BP measurements from the arm advised by the trial site staff. 
10. Take 3 BP measurements with a 1-minute interval between each measurement. 
  
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 43 of 49 
20.4. Appendix 4: Trial Organization 
Steering Committee  
Chair   
 
 
Members  
 
ACC members – non-voting 
  
 
Coordination 
 
 
Data and Safety Monitoring Board 
 
Members  
 
Statisticians 
Executive Secretary  
 
 
Coordination 
 
 
 
  

GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 44 of 49 
20.5. Appendix 5: Prohibited Drugs During the Trial 
Participants receiving the following drugs are not eligible for participation in the trial, and these drugs should 
not be initiated during the trial unless clinically essential and treatment cannot be provided with add-on 
medication as mentioned in Section 8.6, page 22. Past use does not contraindicate eligibility, but any 
prohibited drug should be ceased at or before the Screening visit and a period of at least 2 weeks or 5 half-
lives (whichever is longer) must elapse between permanent drug cessation and randomization. 
 
1. Antihypertensive drugs 
1.1. Non-trial angiotensin receptor blockers 
1.2. Non-trial calcium channel blocker 
1.3. Non-trial diuretics of all types, including thiazide, thiazide-like, loop and potassium sparing 
diuretics 
1.4. Alpha-adrenergic blockers 
1.5. Angiotensin-converting enzyme inhibitors 
1.6. Beta-adrenergic blockers 
1.7. Central alpha-agonists 
1.8. Renin-inhibitors 
1.9. Reserpine 
1.10. Vasodilators 
 
2. Endothelin receptor antagonists 
 
3. Neprilysin inhibitors 
 
4. Other drugs that may affect BP 
4.1. Corticosteroids (e.g. cortisone, hydrocortisone) excluding topical inhaled and intranasal use  
4.2. Liquorice 
4.3. Erythropoiesis stimulating agents (e.g. epoetin alfa) 
4.4. Calcineurin inhibitors (e.g. cyclosporine, tacrolimus) 
4.5. Sodium-glucose co-transporter-2 (SGLT2) inhibitors (eg. dapagliflozin, empagliflozin, 
canagliflozin) 
4.6. Psychiatric drugs that affect blood pressure:70 venlafaxine, bupropion, tricyclics, monoamine 
oxidase inhibitors (MAOis)  
4.7. Cocaine, amphetamines or other stimulants, including the appetite suppressant phentermine 
4.8. Pseudoephedrine, phenylephrine or other nasal decongestants, excluding topical and 
intermittent use 
4.9. Yohimbine 
4.10. Vascular endothelial growth factor pathway inhibitors (e.g. bevacizumab, SORAfenib) 
 
5. Intermittent use of  phosphodiesterase (PDE) inhibitors (eg  sildafenil)  do not constitute a contraindication 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 45 of 49 
20.6. Appendix 6: Protocol Signature Page 
The signatures below constitute approval of this protocol by the signatories and provide the assurances that 
this trial will be conducted according to all stipulations of the protocol, including all statements regarding 
confidentiality, applicable ethical and regulatory requirement, laws and ICH-GCP. 
 
Trial Number: GMRx2-HTN-2020-ACT1 
Indication: Hypertension    
 
 
 
GEORGE MEDICINES CHIEF INVESTIGATOR 
 
 
 
Signature  ___ ________________________________________________ 
 
 
Date   _______________________________________________________________________ 
 
 
Name  ____________________________________________ 
 
 
Title   _______________________________________________________________________ 
  
  
 
 
TRIAL SITE INVESTIGATOR 
 
 
Trial Site Name              
              
             
 
 
Signature  _______________________________________________________________________ 
 
 
Date   _______________________________________________________________________ 
 
 
Name  _______________________________________________________________________ 
 
 
Title   _______________________________________________________________________ 
8 March 2024

GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 46 of 49 
 REFERENCES 
1. Murray CJL, Aravkin AY, Zheng P, . . .Lim SS. Global burden of 87 risk factors in 204 countries and 
territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 
2020;396(10258):1223-49. 
2. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: 
results of prospectively-designed overviews of randomised trials. The Lancet. 2003;362:1527-35. 
3. Ettehad D, Emdin CA, Kiran A, . . .Rahimi K. Blood pressure lowering for prevention of cardiovascular 
disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957-67. 
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular 
disease: meta-analysis of 147 randomised trials in the context of expectations from prospective 
epidemiological studies. BMJ. 2009;338:b1665. 
5. Xie X, Atkins E, Lv J, . . .Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and 
renal outcomes: updated systematic review and meta-analysis. The Lancet. 2016;387(10017):435-43. 
6. Chow CK, Teo KK, Rangarajan S, . . .Diaz R. Prevalence, awareness, treatment, and control of 
hypertension in rural and urban communities in high-, middle-, and low-income countries. Journal of American 
Medical Association. 2013;310(9):959-68. 
7. Beaney T, Burrell LM, Castillo RR, . . .Ramirez AJ. May Measurement Month 2018: a pragmatic global 
screening campaign to raise awareness of blood pressure by the International Society of Hypertension. 
European Heart Journal. 2019;40(25):2006-17. 
8. Benjamin IJ, Kreutz R, Olsen MH, . . .Brainin MJ. Fixed-dose combination antihypertensive medications. 
The Lancet. 2019;394(10199):637-8. 
9. Derington CG, King JB, Herrick JS, . . .Bress AP. Trends in Antihypertensive Medication Monotherapy 
and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016. 
Hypertension. 2020;75(4):973-81. 
10. Abegaz TM, Shehab A, Gebreyohannes EA, . . .Elnour AA. Nonadherence to antihypertensive drugs: A 
systematic review and meta-analysis. Medicine. 2017;96(4):e5641. 
11. Gupta P, Patel P, Štrauch B, . . .Tomaszewski M. Risk Factors for Nonadherence to Antihypertensive 
Treatment. Hypertension. 2017;69(6):1113-20. 
12. van der Laan DM, Elders PJM, Boons CCLM, . . .Hugtenburg JG. Factors associated with 
antihypertensive medication non-adherence: a systematic review. Journal Of Human Hypertension. 
2017;31:687. 
13. Vrijens B, Vincze G, Kristanto P, . . .Burnier M. Adherence to prescribed antihypertensive drug 
treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-7. 
14. Osterberg L, Blaschke T. Adherence to medication. New England Journal of Medicine. 2005;353:487-
97. 
15. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, 
and control in Western Europe and the United States. Archives of internal medicine. 2007;167(2):141-7. 
16. Mu L, Mukamal KJ. Treatment Intensification for Hypertension in US Ambulatory Medical Care. Journal 
of the American Heart Association. 2016;5(10):e004188. 
17. Salam A, Kanukula R, Atkins E, . . .Rodgers AJJoh. Efficacy and safety of dual combination therapy of 
blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of 
randomized controlled trials. Journal of Hypertension. 2019;37(9):1768-74. 
18. Wald DS, Law M, Morris JK, . . .Wald NJ. Combination therapy versus monotherapy in reducing blood 
pressure: meta-analysis on 11,000 participants from 42 trials. American Journal of Medicine. 2009;122(3):290-
300. 
19. Feldman RD, Zou GY, Vandervoort MK, . . .Feagan BG. A Simplified Approach to the Treatment of 
Uncomplicated Hypertension: A Cluster Randomized, Controlled Trial. Hypertension. 2009;53(4):646-53. 
20. Mourad JJ, Waeber B, Zannad F, . . .investigators of the St. Comparison of different therapeutic 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 47 of 49 
strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential 
monotherapy or a stepped-care approach.[Erratum appears in J Hypertens. 2007 Jan;25(1):258]. Journal of 
Hypertension. 2004;22(12):2379-86. 
21. MacDonald TM, Williams B, Webb DJ, . . .Padmanabhan S. Combination Therapy Is Superior to 
Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled 
Trial. Journal of American Heart Association. 2017;6(11):e006986. 
22. Williams B, Mancia G, Spiering W, . . .Group ESCSD. 2018 ESC/ESH Guidelines for the management of 
arterial hypertension. European Heart Journal. 2018;39:3021–104. 
23. Unger T, Borghi C, Charchar F, . . .Schutte AE. 2020 International Society of Hypertension global 
hypertension practice guidelines. Journal of Hypertension. 2020;38(6). 
24. Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health 
Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. 2021. 
25. Whelton PK, Carey RM, Aronow WS, . . .Wright JT. 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, 
Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017. 
26. Bennett A, Chow CK, Chou M, . . .Rodgers A. Efficacy and Safety of Quarter-Dose Blood Pressure–
Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 
2017;70:85–93. 
27. Law MR, Wald NJ, Morris JK, . . .Jordan RE. Value of low dose combination treatment with blood 
pressure lowering drugs: analysis of 354 randomised trials. British Medical Journal. 2003;326:1427-31. 
28. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than 
individual agents--a preliminary report. Hypertension. 2007;49(2):272-5. 
29. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS 
ONE. 2012;7(7):e41297. 
30. Webster R, Salam A, De Silva HA, . . .de Silva APJJ. Fixed low-dose triple combination antihypertensive 
medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri 
Lanka: a randomized clinical trial. JAMA. 2018;320(6):566-79. 
31. Chow C, Bennett A, Thakkar J, . . .Rodgers A. Quarter-dose quadruple combination therapy for initial 
treatment of hypertension – placebo-controlled crossover randomised trial and systematic review The Lancet. 
2017;389(10073):1035-42. 
32. Hong SJ, Sung KC, Lim SW, . . .Rhee MY. Low-Dose Triple Antihypertensive Combination Therapy in 
Patients with Hypertension: A Randomized, Double-Blind, Phase II Study. Drug Des Devel Ther. 2020;14:5735-
46. 
33. Chow CK, Atkins ER, Hillis GS, . . .Klimis H. Initial treatment with a single pill containing quadruple 
combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with 
hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. The Lancet. 
2021;398(10305):1043-52. 
34. Calhoun DA, Lacourciere Y, Chiang YT, . . .Glazer RD. Triple antihypertensive therapy with amlodipine, 
valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32-9. 
35. Chrysant SG, Izzo JL, Jr., Kereiakes DJ, . . .Heyrman R. Efficacy and safety of triple-combination therapy 
with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: 
a subpopulation analysis of the TRINITY study. Journal of the American Society of Hypertension: JASH. 
2012;6(2):132-41. 
36. Mourad J-J, Amodeo C, de Champvallins M, . . .Asmar R. Blood pressure-lowering efficacy and safety 
of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential 
hypertension: a multicenter, randomized, double-blind, controlled trial. Journal of hypertension. 
2017;35(7):1481-95. 
37. Kostis JB, Kim HJ, Rusnak J, . . .Levy E. Incidence and Characteristics of Angioedema Associated With 
Enalapril. Archives of Internal Medicine. 2005;165(14):1637-42. 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 48 of 49 
38. Ricci F, Di Castelnuovo A, Savarese G, . . .De Caterina R. ACE-inhibitors versus angiotensin receptor 
blockers for prevention of events in cardiovascular patients without heart failure—A network meta-analysis. 
International Journal of Cardiology. 2016;217:128-34. 
39. Li ECK, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin 
receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews. 2014(8). 
40. Bangalore S, Fakheri R, Toklu B, . . .Messerli FH. Angiotensin-Converting Enzyme Inhibitors or 
Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From 
Randomized Trials. Mayo Clinic Proceedings. 2016;91(1):51-60. 
41. Israili Z. Clinical pharmacokinetics of angiotensin II (AT 1) receptor blockers in hypertension. Journal 
of Human Hypertension. 2000;14(1):S73-S86. 
42. Zou Z, Xi G, Yuan H, . . .Shi X. Telmisartan versus angiotension-converting enzyme inhibitors in the 
treatment of hypertension: a meta-analysis of randomized controlled trials. Journal of Human Hypertension. 
2009;23(5):339-49. 
43. Liang W, Ma H, Cao L, . . .Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a 
meta-analysis. J Cell Mol Med. 2017;21(11):2634-42. 
44. Roush GC, Ernst ME, Kostis JB, . . .Sica DA. Head-to-head comparisons of hydrochlorothiazide with 
indapamide and chlorthalidone: antihypertensive and metabolic effects. Journal of hypertension. 
2015;65(5):1041-6. 
45. Group SCR. Prevention of stroke by antihypertensive drug treatment in older persons with isolated 
systolic hypertension. JAMA: The Journal of the American Medical Association. 1991;265(24):3255-64. 
46. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes 
in high-risk hypertensive patients randomized to angiotensin-converting enzyme Inhibitor or calcium channel 
blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 
Journal of the American Medical Association. 2002;288:2981-97. 
47. Olde Engberink RHG, Frenkel WJ, van den Bogaard B, . . .van den Born B-JH. Effects of Thiazide-Type 
and Thiazide-Like Diuretics on Cardiovascular Events and Mortality: Systematic Review and Meta-Analysis. 
Hypertension. 2015;65(5):1033-40. 
48. Roush GC, Holford TR, Guddati AK. Chlorthalidone Compared With Hydrochlorothiazide in Reducing 
Cardiovascular Events: Systematic Review and Network Meta-Analyses. Hypertension. 2012;59(6):1110-7. 
49. Thomas J. A review of 10 years of experience with indapamide as an antihypertensive agent. Journal 
of hypertension. 1985;7(6_pt_2):II152. 
50. Khin MU. FDA Briefing Document. Cardiovascular and Renal Drugs Advisory Committee Meeting 
September 10, 2014 To discuss the potential clinical utility of fixed combination prescription drugs composed 
of an antihypertensive drug, aspirin, and a statin administered to reduce the risk of cardiovascular death, 
nonfatal myocardial infarction, and nonfatal stroke in patients with a history of cardiovascular disease. 2014. 
51. Littlejohn TW, Majul CR, Olvera R, . . .Guthrie R. Telmisartan plus amlodipine in patients with moderate 
or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 
4× 4 factorial study. Postgraduate Medicine. 2009;121(2):5-14. 
52. Vogt L, Navis G, Köster J, . . .Zeeuw D. The angiotensin II receptor antagonist telmisartan reduces 
urinary albumin excretion in patients with isolated systolic hypertension: Results of a randomized, double-
blind, placebo-controlled trial. Journal of hypertension. 2005;23(11):2055–61. 
53. Manolis AJ, Reid JL, Zeeuw D, . . .Group AS. Angiotensin II receptor antagonist telmisartan in isolated 
systolic hypertension (ARAMIS) study: Efficacy and safety of telmisartan 20, 40 or 80 mg versus 
hydrochlorothiazide 12.5 mg or placebo. Journal of hypertension. 2004;22(5):1033–7. 
54. Laurent S, Parati G, Chazova I, . . .Farsang C. Randomized evaluation of a novel, fixed-dose combination 
of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. Journal of hypertension. 
2015;33(3):653–62. 
55. Frishman WH, RAM CV, McMahon FG, . . .Hsu H. Comparison of amlodipine and benazepril 
monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-
blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. Journal of clinical 
GMRx2-HTN-2020-ACT1 Protocol 
Version 6.0 
Date:  10 October 2023    
 
 
 
 
Commercial in Confidence  Page 49 of 49 
pharmacology. 1995;35(11):1060–6. 
56. Weidler D, Jallad NS, Curry C, . . .McNally C. Efficacious response with lower dose indapamide therapy 
in the treatment of elderly patients with mild to moderate hypertension. Journal of clinical pharmacology. 
1995;35(1):45–51. 
57. Fiddes R, Blumenthal J, Dawson JE, . . .Niederman AL. Evaluation of indapamide 1.25 mg once daily in 
elderly patients with mild to moderate hypertension. Journal of Human Hypertension. 1997;11(4):239. 
58. Mancia G, Rea F, Corrao G, . . .Grassi G. Two-drug combinations as first-step antihypertensive 
treatment. Journal of Circulation Research. 2019;124(7):1113-23. 
59. Makani H, Bangalore S, Romero J, . . .Messerli FH. Effect of renin-angiotensin system blockade on 
calcium channel blocker-associated peripheral edema. The American Journal of Medicine. 2011;124(2):128-
35. 
60. Guidance for Industry. Electronic Source Data in Clinical Investigations. U.S. Department of Health and 
Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for 
Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), September 2013. 
61. Salam A, Atkins E, ..., . . .Rodgers A. Efficacy and Safety of Triple versus Dual Combination Blood 
Pressure Lowering Therapy - A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal 
of Hypertension. 2019;37(8):1567-73. 
62. Ishikawa J, Carroll DJ, Kuruvilla S, . . .Pickering TG. Changes in home versus clinic blood pressure with 
antihypertensive treatments: a meta-analysis. Journal of Hypertension. 2008;52(5):856-64. 
63. Brown MJ, Williams B, Morant SV, . . .Salsbury J. Effect of amiloride, or amiloride plus 
hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a 
parallel-group, double-blind randomised phase 4 trial. The Lancet Diabetes & Endocrinology. 2015;4(2):136-
47. 
64. Williams B, MacDonald TM, Morant S, . . .British Hypertension Society's Pathway Studies Group. 
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-
resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. The Lancet. 
2015;386(10008):2059-68. 
65. Muntner P, Shimbo D, Carey RM, . . .Wright JT. Measurement of Blood Pressure in Humans: A Scientific 
Statement From the American Heart Association. Hypertension. 2019;73(5):e35-e66. 
66. Reshetnik A, Gohlisch C, Zidek W, . . .van der Giet M. Validation of the Tel-O-GRAPH, a new 
oscillometric blood pressure-measuring device, according to the British Hypertension Society protocol. Blood 
Pressure Monitoring. 2016;21(5):307-9. 
67. Stride BP [Internet].  [cited 15 July 2020]. Available from: https://stridebp.org/bp-monitors . 68. Ding D. Validation of the Foracare Fora D40b upper arm blood pressure monitor, for self 
measurement, according to the European Society of Hypertension International Protocol Revision 2010 
[Internet]. Dublin: dablEducational Trust; 2011 Jul 29. [Available from: 
http://www.dableducational.org/Publications/2011/ESH-IP2010%20Validation%20of%20Foracare%20Fora%20D40b.pdf. 
69. Stergiou GS, Parati G, Imai Y, . . .O’Brien E. Guidelines for Home Blood Pressure Monitoring.  Home 
Blood Pressure Monitoring: Springer; 2020. p. 165-70. 
70. Morreale M, Wake L. Psychiatric Medications and Hypertension. Current Hypertension Reports. 
2020;22(11):1-6. 
 